Literature DB >> 3475172

Phase II study of oral idarubicin in patients with AIDS-associated Kaposi's sarcoma.

A Chachoua, M Green, L Laubenstein, J Wernz, F M Muggia.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3475172

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  6 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer.

Authors:  T Umsawasdi; T B Felder; D Jeffries; R A Newman
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

3.  Phase I study of idarubicin administered orally on a daily x 3 schedule.

Authors:  D J Stewart; S Verma; J A Maroun; L Robillard; D J Perrault; V Young; S Gupta; B Fontaine
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

Review 4.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

Review 5.  Treatment of Kaposi's sarcoma. Current guidelines and future perspectives.

Authors:  D W Northfelt
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

Review 6.  Viral RNA structure-based strategies to manipulate translation.

Authors:  Zane A Jaafar; Jeffrey S Kieft
Journal:  Nat Rev Microbiol       Date:  2019-01       Impact factor: 60.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.